Search Results - "de Dueñas, Eduardo Martinez"

FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease by Garcia-Recio, Susana, Thennavan, Aatish, East, Michael P, Parker, Joel S, Cejalvo, Juan M, Garay, Joseph P, Hollern, Daniel P, He, Xiaping, Mott, Kevin R, Galván, Patricia, Fan, Cheng, Selitsky, Sara R, Coffey, Alisha R, Marron, David, Brasó-Maristany, Fara, Burgués, Octavio, Albanell, Joan, Rojo, Federico, Lluch, Ana, de Dueñas, Eduardo Martinez, Rosen, Jeffery M, Johnson, Gary L, Carey, Lisa A, Prat, Aleix, Perou, Charles M

“…Mechanisms driving tumor progression from less aggressive subtypes to more aggressive states represent key targets for therapy. We identified a subset of…”
Get full text

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01) by Lluch, Ana, Barrios, Carlos H, Torrecillas, Laura, Ruiz-Borrego, Manuel, Bines, Jose, Segalla, Jose, Guerrero-Zotano, Ángel, García-Sáenz, Jose A, Torres, Roberto, de la Haba, Juan, García-Martínez, Elena, Gómez, Henry L, Llombart, Antonio, Bofill, Javier Salvador, Baena-Cañada, José M, Barnadas, Agustí, Calvo, Lourdes, Pérez-Michel, Laura, Ramos, Manuel, Fernández, Isaura, Rodríguez-Lescure, Álvaro, Cárdenas, Jesús, Vinholes, Jeferson, Martínez de Dueñas, Eduardo, Godes, Maria J, Seguí, Miguel A, Antón, Antonio, López-Álvarez, Pilar, Moncayo, Jorge, Amorim, Gilberto, Villar, Esther, Reyes, Salvador, Sampaio, Carlos, Cardemil, Bernardita, Escudero, Maria J, Bezares, Susana, Carrasco, Eva, Martín, Miguel

“…Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial…”
Get full text

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study by Martín, Miguel, Ruiz Simón, Amparo, Ruiz Borrego, Manuel, Ribelles, Nuria, Rodríguez-Lescure, Álvaro, Muñoz-Mateu, Montserrat, González, Sonia, Margelí Vila, Mireia, Barnadas, Agustí, Ramos, Manuel, Del Barco Berron, Sonia, Jara, Carlos, Calvo, Lourdes, Martínez-Jáñez, Noelia, Mendiola Fernández, César, Rodríguez, César A, Martínez de Dueñas, Eduardo, Andrés, Raquel, Plazaola, Arrate, de la Haba-Rodríguez, Juan, López-Vega, Jose Manuel, Adrover, Encarna, Ballesteros, Ana Isabel, Santaballa, Ana, Sánchez-Rovira, Pedro, Baena-Cañada, José M, Casas, Maribel, del Carmen Cámara, María, Carrasco, Eva Maria, Lluch, Ana

“…Capecitabine is an active drug in metastatic breast cancer (BC). GEICAM/2003-10 is an adjuvant trial to investigate the integration of capecitabine into a…”
Get full text

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion by Lluch, Ana, González-Angulo, Ana M., Casadevall, David, Eterovic, Agda K., Martínez de Dueñas, Eduardo, Zheng, Xiaofeng, Guerrero-Zotano, Ángel, Liu, Shuying, Pérez, Ramón, Chen, Ken, Chacón, Jose Ignacio, Mills, Gordon B., Antolín, Silvia, Blancas, Isabel, López-Serra, Paula, Carrasco, Eva, Caballero, Rosalía, Prat, Aleix, Rojo, Federico, Gonzalez-Perez, Abel, Meric-Bernstam, Funda, Albanell, Joan

“…Changes in the clinical subtype (CS) and intrinsic subtype (IS) between breast cancer (BC) metastases and corresponding primary tumours have been reported…”
Get full text

Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis by Blancas, Isabel, Linares-Rodríguez, Marina, Martínez de Dueñas, Eduardo, Herrero-Vicent, Carmen, Molero-Mir, María D., Garrido, José M., Rodríguez-Serrano, Fernando

“…Tamoxifen is a drug used for hormone receptor-positive breast cancers, primarily metabolised by the CYP2D6 enzyme into active metabolites such as endoxifen…”
Get full text

Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer by Di Cosimo, Serena, Pérez-García, José Manuel, Bellet, Meritxell, Dalenc, Florence, Gil Gil, Miguel J., Ruiz-Borrego, Manuel, Gavilá, Joaquín, Aguirre, Elena, Schmid, Peter, Marmé, Frederik, Gligorov, Joseph, Schneeweiss, Andreas, Albanell, Joan, Zamora, Pilar, Wheatley, Duncan, Martínez de Dueñas, Eduardo, Amillano, Kepa, Shimizu, Eileen, Sampayo-Cordero, Miguel, Cortés, Javier, Llombart-Cussac, Antonio

“…The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump…”
Get full text

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers by Milne, Roger L, Osorio, Ana, Ramón y Cajal, Teresa, Baiget, Montserrat, Lasa, Adriana, Diaz-Rubio, Eduardo, de la Hoya, Miguel, Caldés, Trinidad, Teulé, Alex, Lázaro, Conxi, Blanco, Ignacio, Balmaña, Judith, Sánchez-Ollé, Gessamí, Vega, Ana, Blanco, Ana, Chirivella, Isabel, Esteban Cardeñosa, Eva, Durán, Mercedes, Velasco, Eladio, Martínez de Dueñas, Eduardo, Tejada, María-Isabel, Miramar, María-Dolores, Calvo, María-Teresa, Guillén-Ponce, Carmen, Salazar, Raquel, San Román, Carlos, Urioste, Miguel, Benítez, Javier

“…Environmental or lifestyle factors are likely to explain part of the heterogeneity in breast and ovarian cancer risk among BRCA1 and BRCA2 mutation carriers…”
Get full text

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer by Cejalvo, Juan M, Martínez de Dueñas, Eduardo, Galván, Patricia, García-Recio, Susana, Burgués Gasión, Octavio, Paré, Laia, Antolín, Silvia, Martinello, Rosella, Blancas, Isabel, Adamo, Barbara, Guerrero-Zotano, Ángel, Muñoz, Montserrat, Nucíforo, Paolo, Vidal, María, Pérez, Ramón M, Chacón López-Muniz, José I, Caballero, Rosalía, Peg, Vicente, Carrasco, Eva, Rojo, Federico, Perou, Charles M, Cortés, Javier, Adamo, Vincenzo, Albanell, Joan, Gomis, Roger R, Lluch, Ana, Prat, Aleix

“…Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic…”
Get full text

CASP8 D302H polymorphism delays the age of onset of breast cancer in BRCA1 and BRCA2 carriers by Palanca Suela, Sarai, Esteban Cardeñosa, Eva, Barragán González, Eva, de Juan Jiménez, Inmaculada, Chirivella González, Isabel, Segura Huerta, Ángel, Guillén Ponce, Carmen, Martínez de Dueñas, Eduardo, Montalar Salcedo, Joaquín, Castel Sánchez, Victoria, Bolufer Gilabert, Pascual

“…The polymorphic genetic differences among individuals may modify the high risk for breast cancer (BC) and/or ovarian cancer (OC) susceptibility conferred by…”
Get full text

Broad BRCA1 and BRCA2 mutational spectrum and high incidence of recurrent and novel mutations in the eastern Spain population by Esteban Cardeñosa, Eva, Bolufer Gilabert, Pascual, de Juan Jimenez, Inmaculada, Palanca Suela, Sarai, Barragán González, Eva, Chirivella González, Isabel, Segura Huerta, Ángel, Guillén Ponce, Carmen, Martínez de Dueñas, Eduardo

Get full text

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial by Llombart-Cussac, Antonio, Pérez-García, José Manuel, Bellet, Meritxell, Dalenc, Florence, Gil-Gil, Miguel, Ruíz-Borrego, Manuel, Gavilá, Joaquín, Sampayo-Cordero, Miguel, Aguirre, Elena, Schmid, Peter, Marmé, Frederik, Di Cosimo, Serena, Gligorov, Joseph, Schneeweiss, Andreas, Albanell, Joan, Zamora, Pilar, Wheatley, Duncan, Martínez-de Dueñas, Eduardo, Amillano, Kepa, Malfettone, Andrea, Cortés, Javier

“…The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients with…”
Get more information

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial by Di Cosimo, Serena, Pérez-García, José Manuel, Bellet, Meritxell, Dalenc, Florence, Gil Gil, Miguel J, Ruiz Borrego, Manuel, Gavilá, Joaquín, Sampayo-Cordero, Miguel, Aguirre, Elena, Schmid, Peter, Marmé, Frederik, Gligorov, Joseph, Schneeweiss, Andreas, Albanell, Joan, Zamora, Pilar, Wheatley, Duncan, Martínez-De Dueñas, Eduardo, Carañana, Vicente, Amillano, Kepa, Mina, Leonardo, Malfettone, Andrea, Cortés, Javier, Llombart-Cussac, Antonio

“…Palbociclib has gained a central role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced…”
Get full text

Machine Learning Models and Multiparametric Magnetic Resonance Imaging for the Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer by Herrero Vicent, Carmen, Tudela, Xavier, Moreno Ruiz, Paula, Pedralva, Víctor, Jiménez Pastor, Ana, Ahicart, Daniel, Rubio Novella, Silvia, Meneu, Isabel, Montes Albuixech, Ángela, Santamaria, Miguel Ángel, Fonfria, María, Fuster-Matanzo, Almudena, Olmos Antón, Santiago, Martínez de Dueñas, Eduardo

“…Background: Most breast cancer (BC) patients fail to achieve pathological complete response (pCR) after neoadjuvant chemotherapy (NAC). The aim of this study…”
Get full text

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial by Iwata, Hiroji, Chia, Stephen K L, Bashford, Anna, Inoue, Kenichi, Armstrong, Anne C, Wong, Alvin, Buyse, Marc, Harvey, Vernon, Smith, John W., Konstantinovic, Zora Neskovic, Rodriguez, Gladys I., Jáñez Martinez, Noelia, Knoop, Ann Soegaard, De Boer, Richard Hendry, Rai, Yoshiaki, Yamamoto, Naohito, Brincat, Stephen, Papish, Steven William, Manalo, Yvonne, Sorensen, Peter Grundtvig, Aogi, Kenjiro, Shimizu, Satoru, Mainwaring, Paul, Chang, Jose, del Barco Berron, Sonia, Dickerson, Laura C., Klein, Leonard M., Ruxer, Robert, Veyret, Corinne, Wagnerova, Maria, Richards, Donald A., Vasileios, Asskikis, Dourthe, Louis Marie, Lu, Yen-Shen, Greenspan, Andrew R., Gonzalez Santiago, Santiago, Perren, Timothy John, Yau, Chung Cheung Thomas, Pikó, Béla, Sato, Nobuaki, Askoy, Sercan, Altundag, Mustafa Kadri, Saip, Pinar, Bajaj, Rajesh, Vestlev, Peter Michael, Dank, Magdolna, Cinieri, Saverio, Suszko-Kazarnowicz, Malgorzata, Yap, Yoon Sim, Chen, Shin-Cheh, Haley, Barbara Bacsik, Inhorn, Roger C., Koynova, Tatyana, Schneeweiss, Andreas, Cubedo Cervera, Ricardo, Urruticoechea Ribate, Ander, Schwartz, Garry H., Mocharnuk, Robert Scott, Alkhouri, Nabiel, Erickson, Nicholette, Traynor, Ann, Volterra, Fabio, Capo, Gerardo, Flaherty, Lawrence E., Baidas, Said, Lybaert, Willem, Holland, David R., Gonzalez Jimenez, Sonia, Vanlemmens, Laurence, Ruggeri, Enzo Maria, Desai, Ajit, Nixon, David Allen, O'Brien, Edward, Lanier, Keith S., Brescia, Frankie Ann, Richard, Vincent, Geldhof, Kurt, Bednarik, Otakar, Schwedler, Kathrin, Fries, Stefan, Klare, Peter, Griesinger, Frank, Trufflandier, Nathalie, Chetiyawardana, Anula D., Papandreou, Christos, Hornyak, Lajos, Simo, Erzsebet, Im, Seock-Ah, Ruit, Jan B., Ciltas, Aydin, Benekli, Mustafa, Conkright, William A., Ottaviano, Yvonne, Delmas, Andrew, Steele, Heather A., Bova, Abby R., Shirinian, Mihran, O'Rourke, Timothy J., Francisco, Michael, Carrillo Flores, Maria Regina

“…ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after…”
Get full text

Relationship of BRCA1 and BRCA2 mutations with cancer burden in the family and tumor incidence by Esteban Cardeñosa, Eva, Bolufer Gilabert, Pascual, de Juan Jiménez, Inmaculada, Palanca Suela, Sarai, Barragán González, Eva, González Anguix, Virginia, Lerma Alejos, Enrique, Chirivella González, Isabel, Segura Huerta, Ángel, Guillén Ponce, Carmen, Martínez de Dueñas, Eduardo, Cuevas Cuerda, Dolores, Salas Trejo, Dolores

“…The aim of the present study is to analyze the relationship of the incidence of mutations in the two major genes BRCA1 and BRCA2 conferring risk of breast…”
Get full text

Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer by Castillejo, Adela, Hernández-Illán, Eva, Rodriguez-Soler, María, Pérez-Carbonell, Lucía, Egoavil, Cecilia, Barberá, Victor M, Castillejo, María-Isabel, Guarinos, Carla, Martínez-de-Dueñas, Eduardo, Juan, María-Jose, Sánchez-Heras, Ana-Beatriz, García-Casado, Zaida, Ruiz-Ponte, Clara, Brea-Fernández, Alejandro, Juárez, Miriam, Bujanda, Luis, Clofent, Juan, Llor, Xavier, Andreu, Montserrat, Castells, Antoni, Carracedo, Angel, Alenda, Cristina, Payá, Artemio, Jover, Rodrigo, Soto, José-Luis

“…The prevalence of MLH1 constitutional epimutations in the general population is unknown. We sought to analyse the prevalence of MLH1 constitutional…”
Get more information

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial by Llombart-Cussac, Antonio, Pérez-Garcia, José Manuel, Ruiz Borrego, Manuel, Tolosa, Pablo, Blanch, Salvador, Fernández-Ortega, Adela, Urruticoechea, Ander, Blancas, Isabel, Saura, Cristina, Rojas, Beatriz, Bermejo, Begoña, Ponce Lorenzo, José, Gion, María, Cortez-Castedo, Patricia, Llabres, Elisenda, Galve, Elena, Cueva, Juan Fernando, López, Ana, Alonso-Romero, José Luis, González-Santiago, Santiago, Martínez de Dueñas, Eduardo, Ciruelos, Eva, Martrat, Griselda, Gener, Petra, Alcalá-López, Daniel, Sampayo-Cordero, Miguel, Gómez-Peralta, Fernando, Cortés, Javier

“…Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce…”
Get full text

Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer by Zafra-Ceres, Mercedes, de Haro, Tomas, Farez-Vidal, Esther, Blancas, Isabel, Bandres, Fernando, de Dueñas, Eduardo Martinez, Ochoa-Aranda, Enrique, Gomez-Capilla, Jose A, Gomez-Llorente, Carolina

“…Estrogen receptor-positive breast cancer tumors depend on estrogen signaling for their growth and replication and can be treated by anti-estrogen therapy with…”
Get full text

Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype by Martinez de Dueñas, Eduardo, Ochoa Aranda, Enrique, Blancas Lopez-Barajas, Isabel, Ferrer Magdalena, Teresa, Bandrés Moya, Fernando, Chicharro García, Luis Miguel, Gómez Capilla, José A, Zafra Ceres, Mercedes, de Haro, Tomás, Romero Llorens, Regina, Ferrer Albiach, Carlos, Ferriols Lisart, Rafael, Chover Lara, Dolores, López Rodríguez, Ángela, Munárriz Ferrandis, Javier, Olmos Antón, Santiago

“…Abstract Background CYP2D6 is a key enzyme in tamoxifen metabolism, transforming it into its main active metabolite, endoxifen. Poor CYP2D6 metabolizers (PM)…”
Get full text

Abstract OT2-19-06: Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL by Llombart-Cussac, Antonio, Gligorov, Joseph, Di Cosimo, Serena, Albacar, Cinta, Cortez, Patricia, Martinez-De Dueñas, Eduardo, López, Ana, Carañana, Vicente, Medioni, Jacques, Cavanna, Luigi, Cazzaniga, Marina Elena, Braga, Sofia, Coelho, Passos, Sampayo-Cordero, Miguel, Malfettone, Andrea, Pérez-García, José Manuel, Cortes, Javier

“…Background: Endocrine therapy (ET) is the preferred therapy option for patients (pts) with hormone receptor-positive (HR[+]) advanced breast cancer (ABC),…”
Get full text